Effect of Platelet Inhibition and / or Lipid Lowering in Non-ACS-patients With Positive Troponin

• Status: Recruiting
• Trial end date: 2023-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The study evaluates the effect of platelet inhibition and / or lipid lowering in non-ACS-patients with symptoms suggestive for ACS, and elevated high-sensitivity troponin values

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dr. med. Mahir Karakas; Universitätsklinikum Hamburg-Eppendorf
• Treatments: Aspirin; Atorvastatin; Atorvastatin Calcium

Criteria

Inclusion Criteria:

• Patient with symptoms suggestive for ACS presenting within 48 hours after onset in the ER/ Chest Pain Unit (CPU)

• Patient has at least one elevated high-sensitivity troponin I or T value

• Chest pain is classified as non-ACS, despite elevated hsTn (e.g. because of missing troponin dynamics)

• At least 50 years of age

Exclusion Criteria:

• Indication for antiplatelet therapy (e.g transient ischemic attack, or stable coronary artery diseases -CAD) or anticoagulation therapy (such as atrial fibrillation)

• Indication for anti-lipid therapy

• Any evidence of an acute myocardial necrosis (e.g imaging evidence of new regional wall motion abnormality, or significant ST-segment-T wave (ST-T) changes in ECG)

• Untreated clinically significant CAD requiring revascularization

• Hemoglobin value below 8 mg/d, and/or creatinine kinase ≥3 times ULN, and/or AST or ALT ≥3 times ULN

• Active malignancy of any organ system, treated or untreated. Subjects have to be in remission for at least 36 months to be eligible.